Copyright
©The Author(s) 2022.
World J Clin Cases. Jan 21, 2022; 10(3): 790-801
Published online Jan 21, 2022. doi: 10.12998/wjcc.v10.i3.790
Published online Jan 21, 2022. doi: 10.12998/wjcc.v10.i3.790
Table 2 Grouping analysis of the relationship between tumor mutation burden and overall survival
Median survival (mo) | Log-rank test | |||
TMB-high | TMB-low | HR | P value | |
Tumor grade | ||||
Well differentiated | - (n = 5) | 56.1 (n = 10) | 0.64 (0.15-2.27) | 0.582 |
Moderately differentiated | 26.5 (n = 79) | 42.5 (n = 134) | 1.46 (1.02-2.08) | 0.026 |
Poorly differentiated | 20.2 (n = 52) | 29.8 (n = 82) | 1.72 (1.11-2.66) | 0.007 |
Disease progression | ||||
Solitary liver tumor | 55.1 (n = 44) | 69.4 (n = 93) | 1.42 (0.85-2.38) | 0.140 |
Multifocal liver disease | 24.4 (n = 31) | 40.6 (n = 46) | 1.85 (1.00-3.43) | 0.026 |
Metastatic disease | 15.5 (n = 65) | 15.8 (n = 100) | 1.17 (0.83-1.66) | 0.357 |
Tumor resection | ||||
Resected | 36.6 (n = 67) | 61.5 (n = 127) | 1.77 (1.17-2.66) | 0.002 |
Unresected | 17.5 (n = 73) | 17.7 (n = 112) | 1.13 (0.81-1.59) | 0.461 |
- Citation: Song JP, Liu XZ, Chen Q, Liu YF. High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma. World J Clin Cases 2022; 10(3): 790-801
- URL: https://www.wjgnet.com/2307-8960/full/v10/i3/790.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i3.790